DOJO today announces the launch of the BLAST10K Fresh, the first device in the UK market to feature proprietary INSTA-JUICED technology. Utilising a unique 0+10ml freshness-locking structure, this innovative vape isolates e-liquid from the coil until activation. Unlike traditional devices where prolonged contact with the coil can lead to oxidation and stale flavours, INSTA-JUICED keeps the liquid pristine. This ensures that the flavour profile remains locked at its peak—delivering vibrant sweetness and sharp cooling—effectively providing a “just-opened” experience with every puff. This design addresses consumer concerns regarding flavour degradation, retaining over 70% more freshness than other products even after long-term storage.

At the heart of the BLAST10K Fresh is DOJO’s advanced COREX BLAST technology paired with a Dual Mesh coil design. This combination guarantees consistent heat distribution and optimal wicking, delivering a True Fresh Flavour that remains vibrant from the first puff to the last. By eliminating flavour drop-off across its 10,000-puff lifespan, the device ensures a Long-Lasting experience where every draw tastes as authentic as the beginning. Supporting this performance is a robust 1000mAh rechargeable battery, offering up to three days of use on a single charge, alongside SSS Leak-Resistant Tech for superior leak protection.

The launch introduces eight exclusive, nature-inspired flavours, headlined by the industry-first Matcha Strawberry. This sophisticated profile is inspired by the delicate balance of British Malling Centenary strawberries and Japanese Okumidori matcha, capturing their authentic essences with a smooth, creamy finish to offer a premium café-style experience. Other notable launches include Pina Colada, which evokes the tropical notes of Costa Rican pineapple and coconut, and Berry Lemonade, a zesty fusion reminiscent of strawberries, raspberries, and Meyer lemons. These join existing favourites like Rhubarb Custard Sweet and Blackcurrant GB, expanding the BLAST series portfolio to 40 distinct options.

Crucially, the BLAST10K Fresh maintains full compatibility with the broader BLAST ecosystem, supporting both new 0+10ml pods and existing 2+8ml pods for seamless user transition. “The BLAST10K Fresh redefines premium vaping by solving flavour stagnation,” stated a DOJO spokesperson. “We invite consumers to experience unparalleled consistency and freshness.”

The DOJO BLAST10K Fresh will be available at selected UK retailers soon.

For more information, please visit:

https://www.dojovape.com/blast10k-fresh
https://www.dojovape.com/
https://dojovape.co.uk/

About DOJO

DOJO is dedicated to providing adult vapers with innovative, high-quality devices that prioritise flavour integrity and user satisfaction through cutting-edge technology.

Source link

“The state is working really hard to operationalize this program as quickly as possible. People are suffering and they want to address that suffering.”

By Leah Romero, Source NM

New Mexico’s Medical Psilocybin Program recently opened up applications for producers of the psychedelic mushroom, marking a significant step toward the therapeutic program becoming fully operational.

“We’re no longer talking about a piece of legislation and some rulemaking. This is real, this is happening and it’s being operationalized right now,” Santa Fe-based psychedelic attorney Victoria Cvitanovic told Source NM.

The program was created last year with the signing of Senate Bill 219, which created the medical psilocybin program, an advisory board and legalized use of the psychedelic in controlled, therapeutic settings. Qualifying conditions currently include major treatment-resistant depression, post traumatic stress disorder, substance use disorders and end-of-life care.

The New Mexico Department of Health Center for Medical Cannabis and Psilocybin began accepting applications last week from potential producers to grow the mushrooms for future program participants.

Cvitanovic told Source that the application is intended to ensure the psilocybin “produced for this program in New Mexico is both safe and medically beneficial for patients, as well as that this doesn’t cause safety issues for people in New Mexico generally.”

According to the permit requirements, applicants must provide a state business license; proof of registration with the New Mexico Secretary of State and the Taxation and Revenue Department; facility safety documents; proof of ownership of the facility or a signed statement from the landowner; proof of compliance with city and county zoning requirements; and verification that psilocybin products will only be produced and tested in New Mexico.

“I think it’s notable that the application balances both the safety of the patients who will be receiving the end product and the safety of people who may live in areas of the state where someone is granted a license to produce psilocybin,” Cvitanovic said. “These applications are open to anyone, but they are fairly extensive because of the high stakes of producing a controlled substance, specifically for very limited medical use.”

She said she believes that most applicants will have an agricultural and entrepreneurial background, but likely only a small number of “highly qualified” applications will meet the requirements.

A DOH spokesperson told Source NM in an email that there is currently no deadline for applications and that they will be reviewed in order of submission.

Cvitanovic said she recommends those considering applying to be a producer confer with a lawyer and accountant and get documentation together to submit the most complete and compliant application as possible. However, they should also consider whether their plans are operational if a permit is granted.

SB219 set a deadline of December 31, 2027 for the psilocybin program to be implemented; however, the state committed to expediting the timeline by a year, aiming to open the program to its first patients by the end of 2026.

“The state is working really hard to operationalize this program as quickly as possible,” Cvitanovic said. “People are suffering and they want to address that suffering.”

She added that the program’s rulemaking process is not complete and more permit applications will open up down the line for testing and for qualified clinicians. A “buildout and inspection period” will also likely follow before treatment begins with patients. She encouraged people interested in participating in the program to speak with their behavioral health providers about becoming certified to facilitate the treatment.

“Programs like this are only as strong as the clinicians and therapists and other people who choose to participate in them. This is hard work, and it is not risk free, but it has the ability to change the lives of thousands of New Mexicans who are suffering,” Cvitanovic said.

This story was first published by Source NM.

Photo courtesy of Alan Rockefeller.

Source link

The Canadian government is investing $24 million to establish the Canadian Cannabis and Brain Health Consortium. The new consortium will include 10 multidisciplinary research teams that will investigate topics ranging from the therapeutic potential of cannabis to its effects on brain health, sleep, prenatal exposure, and among people with conditions such as psychosis, post-traumatic stress disorder, and epilepsy. 

In a statement, Minister of Health Marjorie Michel said the investment “will bring together researchers from across the country to advance our understanding of how cannabis affects brain health and generate knowledge that helps improve care, inform policy and supports the health of Canadians.” 

Dr. Patricia Conrod, scientific director for the Canadian Institutes of Health Research Institute of Neurosciences, Mental Health and Addiction, said in the statement that the consortium “will help researchers build a stronger understanding of how cannabis affects people’s health at every stage of life, generating knowledge that can guide prevention, care and evidence-informed policies for years to come.” 

In 2025, more than one in three Canadian adults reported consuming cannabis, and the 2024 Legislative Review of the Cannabis Act examined how the broad legalization of cannabis in 2018 has impacted the country. The consortium is meant to address key knowledge gaps identified in that review. 

Ganjapreneur: Offering daily insights since 2014, the leading digital business journal for cannabis industry professionals. Subscribe to the newsletter to join our community of over 40,000 ganjapreneurs.

Source link

A medical cannabis patient has launched what is believed to be the world’s first motorsport team for prescribed patients after completing 15 drag racing runs at a circuit where he had previously been excluded from competition.

The PatientsCann UK Motorsport Team, founded under the campaign banner “Driving Out Cannabis Stigma,” aims to raise questions about whether prescribed medical cannabis patients should face blanket exclusion from motorsport or be assessed through evidence-based medical and anti-doping processes like other prescribed medications.

Sal Aziz, director of PatientsCann UK, completed the runs at Thruxton Retro Drag Racing on 4 July following approval through NORA Motorsports and Straightliners. He had previously been excluded from Motorsport UK-regulated activity because of his legal prescription.

Thruxton is where Aziz first entered motorsport as a marshal before his exclusion. Returning to compete at the same venue demonstrated what he calls the contradiction at the heart of UK Motorsport’s approach to medical cannabis patients.

Correspondence from Motorsport UK, seen by leafie, confirms its current position that medicinal cannabis use “in any capacity” is prohibited for officials, competitors, marshals and team members. When contacted, a Motorsport UK spokesperson confirmed that “following extensive review, the use of medicinal cannabis is prohibited for those in safety-critical roles at our Permitted Events,” and that “the effects of such medication have been assessed specifically in the context of motorsport, considering the specific risks and safety obligations that motorsport inherently presents.”

“We take our responsibilities under the Equality Act 2010 very seriously; this is a safety measure kept under regular review in line with the latest safety evidence,” the spokesperson added.

NORA’s approval of Aziz followed what he describes as an evidence-based assessment process. The 15 runs took place in a live motorsport environment at Thruxton, where Motorsport UK events were also taking place.

“To be racing there, literally in the middle of a motorsport environment where Motorsport UK activity was also taking place, showed exactly why this conversation matters,” Aziz said. “One system says patients like me should be excluded, while another evidence-based route has shown we can take part safely and responsibly.”

Aziz has received confirmation from motorsport authorities in Malta and Australia that prescribed medical cannabis patients may be considered through WADA Therapeutic Use Exemption routes, subject to medical evidence and anti-doping requirements. Sport Integrity Australia confirms that cannabis/THC is prohibited in-competition under WADA rules, but that an anti-doping violation only arises where an athlete tests positive without a valid therapeutic use exemption.

The PatientsCann UK Motorsport Team will support patients exploring routes into grassroots motorsport disciplines, drag racing, sim racing and disability-accessible formats. The organisation plans to publish guidance for medical cannabis patients who want to understand how they may participate in motorsport responsibly, and will begin collating results from patients who compete.

Medical cannabis has been legal on prescription in the UK since 2018, yet patients continue to face stigma and misunderstanding around driving, employment, sport and housing.

PatientsCann UK is calling on motorsport bodies, clubs, venues and event organisers to reconsider how medical cannabis patients are treated. The organisation argues patients should be considered through transparent, evidence-based processes that account for medical documentation, anti-doping rules and proportionate safeguards, rather than facing automatic exclusion because of a legal prescription.

Source link

The U.S. Department of Veterans Affairs (VA) is launching a new clinical trial to investigate whether psilocybin can help military veterans who are struggling with treatment-resistant depression.

The move follows VA’s recent announcement of a separate trial on MDMA-assisted therapy in treating veterans with severe mental health disorders, including PTSD and alcohol use disorder.

The new psilocybin and depression research announced on Wednesday, titled “Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression,” or PIVOT, will also include veterans concurrent PTSD.

The randomized, controlled trial—which comes on the heels of an executive order President Donald Trump signed in April with the aim of expediting psychedelic therapy access—will be conducted at five separate VA medical centers across Alabama, Oregon, Pennsylvania and Washington State.

“Far too many veterans are living with mental health conditions that don’t respond to available treatments,” VA Secretary Doug Collins said in a press release. “Under President Trump, VA is pursuing all avenues to evaluate new treatments and offer meaningful relief for those who have worn the uniform. This clinical trial reflects another step toward this goal.”

The psilocybin study will compare outcomes between two different dosage levels and will assess levels of depression before and after the psychedelic treatment, as well as tolerability of side effects.

The research “reflects VA’s commitment to pursuing innovative solutions for veterans who have not responded to existing treatments,” the department said in a press release.

Collins, the VA secretary, recently touted psychedelic therapy development at an event in Florida, saying that “we’re making massive progress in how we diagnose things, but also how we do new treatments, which in the past was more of a wait-and-see approach, and now we’re being more cutting-edge.”

Last month, VA and the Department of Health and Human Services (HHS) launchd a new partnership to collaborate on research and development of psychedelic medicines to treat people struggling with serious mental health conditions.

HHS Secretary Robert F. Kennedy Jr. said recently that the Trump administration is “very anxious” to create a pathway for access to psychedelics therapy and that top officials across federal agencies want to “get it out to the public as quickly as possible.”

In an interview on the Joe Rogan Experience in February, Kennedy said he’s confident “we’re going to get it done,” with plans to develop and finalize rules that would enable patients with conditions such as post-traumatic stress disorder (PTSD) and depression to access psychedelic substances like psilocybin and MDMA in a “very controlled setting.”

“Everybody in my agency…is very anxious to get a rule out there that will allow these kind of studies and will allow access under therapeutic settings, particularly [for] the military soldiers who have suffered these injuries to get access to these products,” the HHS secretary said. “We’re working through that process now. We’re all working on it and trying to make it happen.”

“I think that we’re going to get it done,” he said.

Last June, Kennedy said his agency is “absolutely committed” to expanding research on the benefits of psychedelic therapy and, alongside of the head of FDA, is aiming to provide legal access to such substances for military veterans “within 12 months.”

Collins disclosed last year that he had an “eye-opening” talk with Kennedy about the therapeutic potential of psychedelic medicine. And he said he’s open to the idea of having the government provide vouchers to cover the costs of psychedelic therapy for veterans who receive services outside of VA as Congress considers pathways for access.

Photo courtesy of Mark Groeneveld.

Source link

UK cannabinoid-based medicines manufacturer, 113 Botanicals, is raising £2 million to help launch its first controlled-release capsule, designed to improve dosing consistency and expand options for patients and prescribers.

Working in partnership with scientists at the University of Sussex since 2020, the company is developing new product formats which it believes could ‘revolutionise’ how cannabis-based medicines are prescribed in the UK.

The raise, which has been launched via Crowdcube, comes as the team prepares to reach a major regulatory milestone and bring its lead product to market in early 2026.

In development for two years, the SpheriCann capsule uses patent-protected technology to deliver a controlled and sustained release effect, which is designed to allow for more consistent absorption and precise dosing of cannabinoid medicines, avoiding the need for multiple doses throughout the day. 

‘Higher bioavailability’

Cannabis plant extracts generally have poor water solubility, meaning it can be “challenging” to deliver clinically viable doses into the body in a “reliable, controlled and predictable manner”, explained 113 Co-Founder and Chief Technical Officer, Mazin Nicola, a chartered chemist and visiting research fellow at the University of Sussex, who spent over 20 years in drug process development at GSK.

SpheriCann is said to have a higher bioavailability than standard capsules and other ingestible administration methods, with University of Sussex-based research showing 75%-95% dissolution into the blood, in a time-controlled release over several hours.

“Standard capsules and other ingestible administration methods have serious drawbacks, including high losses of therapeutic activity to gastric acid degradation and poor dissolution into the bloodstream,” said Nicola.

“Our Sphericann technology addresses the problem of providing relatively high unit dosage forms of CBPM compositions whilst enabling the release of the active pharmaceutical ingredients (APIs) from the dosage form in a linear and prolonged fashion, for example, up to seven hours. Thus, avoiding the need for frequent multi-dosing or delivering a large hit of the cannabis in the composition too quickly.”

Photo: 113 Botanicals

He explained: “This is achieved by formulating a cohesive mass of cannabis extract, a liquid vehicle plus special excipients within a polymeric matrix material. The wet mass is treated to form uniform spheroidal pellets, uniquely identified as ‘Liquipellets’, which are finally contained in gastric acid-resistant capsules. The liquipellets comprise a disintegrant that allows the release of the APIs at a controlled rate.”

According to Nicola, this is different to most known methods of pharmaceutical production, and aims to enable clinicians to prescribe more accurate and controlled dosing of CBMPs, which can be self-administered by the patient with low or no risk of accidental overdose.

Growing demand for alternative product formats 

As access to medical cannabis continues to expand, with some estimates suggesting that up to 80,000 patients will have received treatment in 2025, there is a growing demand for alternative product formats outside of flower and oils.

“We are addressing the lack of meaningful format choice for patients,” said Kate Cook, Co-Founder and COO of 113 Botanicals, speaking to Cannabis Health.

“We have developed delivery formats that are designed for precise dosing and sustained-release, but that also offer convenience, discretion and accessibility.”

The company has forecasted it will reach 5,000 patients in the first 12 months, generating an estimated £8.5 million in revenue.

Cook continued: “We believe that presenting CBMPs in more standardised, pharmaceutically acceptable formats will inspire more confidence in prescribers and have the potential to open up whole new patient groups to the potential benefits of medical cannabis.”

Photo: 113 Botanicals

A regulatory milestone

With Home Office Controlled Drugs Licences at both its R&D laboratory and production facility, 113 is now in the validation phase of its ‘Manufacturers’ Specials’ (MS) license approval from the Medicines and Healthcare Regulatory Agency (MHRA) following a successful remote inspection.

Cook has found the regulator to be “very helpful” throughout the process and is aiming to gain full licence approval following the final inspection, which has been requested for early 2026.

She believes once approved, this will make them one of only a handful of UK medical cannabis companies with an MS licence and the only one to have a licence for a ‘defined novel finished product’.

The Crowdcube campaign follows earlier funding rounds totalling more than £2.8 million, from angels, founders and early supporters to build the manufacturing site, complete R&D work, and prepare for licensing.

Running for three weeks, it aims to raise an additional £2 million to support the launch of SpheriCann and advance its other products, including a 24-hour transdermal patch, VetiCann, to market.

“Above all, we see 113 as an innovator,” Cook added.

“One that harnesses exemplary research and development to create products that revolutionise the way patients can take medical cannabis.”

Source link